🇺🇸 FDA
Patent

US 9222086

Compositions and methods for silencing genes expressed in cancer

granted A61KA61K31/7105A61K31/713

Quick answer

US patent 9222086 (Compositions and methods for silencing genes expressed in cancer) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Dec 24 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Dec 29 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 24 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
8
CPC classes
A61K, A61K31/7105, A61K31/713, A61P, A61P35/00